Results 221 to 230 of about 11,362,691 (296)

Status and future of recombinant adeno‐associated virus vector manufacturing

Biotechnology Progress, EarlyView.
Abstract Sixty years of adeno‐associated virus (AAV) research illustrates a trajectory marked by basic science exploration, iterative innovation, persistent challenges, a number of clinical setbacks, as well as commercial therapeutic triumphs. This continual evolution has led to recombinant AAV (rAAV) becoming a cornerstone of modern gene therapy ...
Frank Agbogbo, David Dismuke
wiley   +1 more source

The low-density lipoprotein receptor contributes to carotenoid homeostasis by regulating tissue uptake and fecal elimination. [PDF]

Mol Metab
Miller AP, Monroy WC, Soria G, Amengual J.   +3 more
europepmc   +1 more source

Clinical Outcomes of Drug‐Eluting Stents and Drug‐Coated Balloons in Tortuous Small Coronary Lesions

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background In small, tortuous coronary lesions, the long‐term comparative performance of drug‐coated balloon (DCB) angioplasty versus drug‐eluting stent (DES) treatment remains uncertain, despite both strategies being widely used in contemporary percutaneous coronary intervention (PCI) practice. Aims This study aimed to compare 3‐year clinical
Shunichiro Ishio, Takashi Nagasaka, Ryota Taniuchi, Shiro Amanai, Yohei Ishibashi, Noriaki Takama, Hideki Ishii   +6 more
wiley   +1 more source

20( S )-Protopanaxatriol Improves Atherosclerosis by Inhibiting Low-Density Lipoprotein Receptor Degradation in ApoE KO Mice. [PDF]

J Cardiovasc Pharmacol
Huang YW, Luo F, Zhang M, Wang L, Meng W, Hu D, Yang J, Sheng J, Wang X.   +8 more
europepmc   +1 more source

Clinical Impact of Adherence to Fractional Flow Reserve Guidance in Acute Coronary Syndrome

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Fractional flow reserve (FFR) is established to guide revascularization in stable coronary disease and non‐culprit lesions in acute coronary syndromes (ACS). However, real‐world adherence to FFR guidance across the spectrum of ACS presentations, including ambiguous culprit scenarios, remains incompletely characterized.
Eun Ho Choo, Ik Jun Choi, Sungmin Lim, Donggyu Moon, Dae‐Won Kim, Kiyuk Chang   +5 more
wiley   +1 more source

Five‐Year Clinical Outcomes of Biodegradable Versus Durable Polymer Drug‐Eluting Stents: A Propensity Score‐Matched Analysis of 4394 Patients

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Biodegradable‐polymer (BP) drug‐eluting stents (DES) were developed to mitigate potential late adverse events related to persistent durable polymers in durable‐polymer (DP) DES; however, contemporary long‐term real‐world comparative data remain limited. Aims We aimed to compare the 5‐year clinical outcomes of contemporary BP‐DES and
Yangyoun Lee, Hong‐Seok Lim, Kyoung‐Woo Seo, Hyoung‐Mo Yang, So‐Yeon Choi, Seung‐Jea Tahk, Myeong‐Ho Yoon   +6 more
wiley   +1 more source

Correction to "Tumor-Activatable Nanoparticles Target Low-Density Lipoprotein Receptor to Enhance Drug Delivery and Antitumor Efficacy". [PDF]

Adv Sci (Weinh)
europepmc   +1 more source

Myasthenia gravis with double-seropositive acetylcholine receptor and low-density lipoprotein receptor-related protein 4 antibodies combined with muscle atrophy: a case report and literature review. [PDF]

Front Immunol
Zheng YL, Su GZ, Li YL, Du T, Zhao XL, Wang CC, Liu Y, Liu B, Duan RS, Li XL.   +9 more
europepmc   +1 more source

Triglyceride Polygenic Score Identifies Individuals Who May Respond Differently to Aspirin in Primary Prevention

Clinical Pharmacology &Therapeutics, EarlyView.
Low‐dose aspirin is no longer routinely recommended for the primary prevention of cardiovascular disease in older adults due to a lack of net benefit over bleeding risk. We hypothesized that genetic subgroups may experience differential harm or benefit from aspirin therapy.
Peter D. Fransquet, Chenglong Yu, Cammie Tran, Sultana Monira Hussain, Chad A. Bousman, Mark R. Nelson, Andrew M. Tonkin, John J. McNeil, Paul Lacaze   +8 more
wiley   +1 more source

Statins, but not proprotein convertase subtilisin-kexin type 9 inhibitors, lower chemerin in hypercholesterolemia via low-density lipoprotein receptor upregulation. [PDF]

MedComm (2020)
Tan L, Wang N, Galema-Boers AMH, van Vark-van der Zee L, van Lennep JR, Mulder MT, Lu X, Danser AHJ, Verdonk K.   +8 more
europepmc   +1 more source